Literature DB >> 29900958

A Systemic Lupus Erythematosus Patient With Febrile Neutropenia Developing After Intraocular Administration of Bevacizumab.

Hamdi Sözen1, Gönen Mengi2, Bülent Hüddam3, Selmin Çaylak1, Mehmet Deveer4, Volkan Karakuş5, Burak Ekrem Çitil6.   

Abstract

In this article, we report a case with febrile neutropenia occurring after implementation of intraocular bevacizumab. A 60-year-old female patient who had received intravitreal bevacizumab applied to hospital for oral lesions accompanying fever and neutropenia. In spite of empiric antibiotherapy, patient's clinical condition did not improve. Her sputum culture yielded Stenotrophomonas maltophilia. Trimethoprim/ sulfamethoxazole and levofloxacin were commenced according to antibiogram. In immunologic evaluation, antinuclear antibodies and anti-double stranded deoxyribonucleic acid were positive as compatible with systemic lupus erythematosus. After proper antibiotic treatment, patient's clinical symptoms resolved. Development of severe neutropenia after procedures which are not expected to create systemic adverse effects should bring to mind underlying immunosuppressive diseases such as systemic lupus erythematosus.

Entities:  

Keywords:  Bevacizumab; Stenotrophomonas maltophilia; febrile neutropenia; systemic lupus erythematosus

Year:  2016        PMID: 29900958      PMCID: PMC5827835          DOI: 10.5606/ArchRheumatol.2016.5747

Source DB:  PubMed          Journal:  Arch Rheumatol        ISSN: 2148-5046            Impact factor:   1.472


  9 in total

Review 1.  Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis.

Authors:  Vishal Ranpura; Sanjaykumar Hapani; Shenhong Wu
Journal:  JAMA       Date:  2011-02-02       Impact factor: 56.272

2.  Clinical characteristics and prognostic factors of patients with Stenotrophomonas maltophilia bacteremia.

Authors:  Chung-Hsu Lai; Chih-Yu Chi; Hsin-Pai Chen; Te-Li Chen; Chorng-Jang Lai; Chang-Phone Fung; Kwok-Woon Yu; Wing-Wai Wong; Cheng-Yi Liu
Journal:  J Microbiol Immunol Infect       Date:  2004-12       Impact factor: 4.399

3.  A case of an SLE patient with febrile neutropenia who experienced exacerbation of cutaneous manifestations after the administration of G-CSF.

Authors:  Takashi Sakai; Yutaka Hatano; Itomi Abe; Koji Ishii; Sakuhei Fujiwara
Journal:  Mod Rheumatol       Date:  2012-08-30       Impact factor: 3.023

Review 4.  The management of peripheral blood cytopenias in systemic lupus erythematosus.

Authors:  Alastair L Hepburn; Santosh Narat; Justin C Mason
Journal:  Rheumatology (Oxford)       Date:  2010-09-07       Impact factor: 7.580

Review 5.  Attributable mortality of Stenotrophomonas maltophilia infections: a systematic review of the literature.

Authors:  Matthew E Falagas; Antonia C Kastoris; Evridiki K Vouloumanou; Petros I Rafailidis; Anastasios M Kapaskelis; George Dimopoulos
Journal:  Future Microbiol       Date:  2009-11       Impact factor: 3.165

Review 6.  Understanding the epidemiology and progression of systemic lupus erythematosus.

Authors:  Guillermo J Pons-Estel; Graciela S Alarcón; Lacie Scofield; Leslie Reinlib; Glinda S Cooper
Journal:  Semin Arthritis Rheum       Date:  2009-01-10       Impact factor: 5.532

7.  Systemic adverse events after intravitreal bevacizumab versus ranibizumab for age-related macular degeneration: a meta-analysis.

Authors:  Wei Wang; Xiulan Zhang
Journal:  PLoS One       Date:  2014-10-16       Impact factor: 3.240

Review 8.  Haematological manifestations of lupus.

Authors:  Anum Fayyaz; Ann Igoe; Biji T Kurien; Debashish Danda; Judith A James; Haraldine A Stafford; R Hal Scofield
Journal:  Lupus Sci Med       Date:  2015-03-03

Review 9.  Clinical use of Bevacizumab in treating refractory glaucoma.

Authors:  V Popescu; S Pricopie; M Totir; R Iancu; S Yasyn; C Alexandrescu
Journal:  J Med Life       Date:  2015 Jan-Mar
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.